Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Legend Biotech

EU flag

EU establishes €100m funding scheme for projects tackling public health threats

The HERA Invest fund will focus on health emergency prevention and preparedness initiatives

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

EU flag

European Commission approves Amicus Therapeutics’ Pompe disease therapy

The company can now offer Opfolda together with its previously-approved Pombiliti

EU flag

European Commission grants two new marketing authorisations for UCB’s Bimzelx

The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links